EGFR and non-small cell lung carcinoma: The third‐generation EGFR‐TKI is an irreversible selective TKI, which specifically targets EGFR T790M and EGFR activating mutations and has been proven effective in patients with EGFR T790M‐positive NSCLC following acquired resistance to prior EGFR‐TKIs.6, 7